G
Gary S. Hoffman
Researcher at Cleveland Clinic
Publications - 262
Citations - 20212
Gary S. Hoffman is an academic researcher from Cleveland Clinic. The author has contributed to research in topics: Vasculitis & Granulomatosis with polyangiitis. The author has an hindex of 69, co-authored 258 publications receiving 18285 citations. Previous affiliations of Gary S. Hoffman include National Institutes of Health & Cleveland Clinic Lerner College of Medicine.
Papers
More filters
Journal ArticleDOI
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
John H. Stone,Peter A. Merkel,Robert Spiera,Philip Seo,Carol A. Langford,Gary S. Hoffman,Cees G. M. Kallenberg,E. William St. Clair,Anthony M. Turkiewicz,Nadia K. Tchao,Lisa Webber,Linna Ding,Lourdes P. Sejismundo,Kathleen Mieras,David Weitzenkamp,David Ikle,Vicki Seyfert-Margolis,Mark Mueller,Paul Brunetta,Nancy B. Allen,Fernando C. Fervenza,Duvuru Geetha,Karina A. Keogh,Eugene Y. Kissin,Paul A. Monach,Tobias Peikert,Coen A. Stegeman,Steven R. Ytterberg,Ulrich Specks +28 more
TL;DR: Rituximab therapy was not inferior to daily cyclophosphamide treatment for induction of remission in severe ANCA-associated vasculitis and may be superior in relapsing disease.
Journal ArticleDOI
Efficacy of Remission-Induction Regimens for ANCA-associated Vasculitis
Ulrich Specks,Peter A. Merkel,Philip Seo,Robert Spiera,Carol A. Langford,Gary S. Hoffman,Cees G. M. Kallenberg,E. William St. Clair,Barri J. Fessler,Linna Ding,Lisa Viviano,Nadia K. Tchao,Deborah Phippard,Adam Asare,Noha Lim,David Ikle,Brett Jepson,Paul Brunetta,Nancy B. Allen,Fernando C. Fervenza,Duvuru Geetha,Karina A. Keogh,Eugene Y. Kissin,Paul A. Monach,Tobias Peikert,Coen A. Stegeman,Steven R. Ytterberg,Mark Mueller,Lourdes P. Sejismundo,Kathleen Mieras,John H. Stone +30 more
TL;DR: In patients with severe ANCA-associated vasculitis, a single course of rituximab was as effective as continuous conventional immunosuppressive therapy for the induction and maintenance of remissions over the course of 18 months.
Journal ArticleDOI
A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis.
Gary S. Hoffman,Maria C. Cid,David B. Hellmann,Loïc Guillevin,John H. Stone,John T. Schousboe,Pascal Cohen,Leonard H. Calabrese,Howard Dickler,Peter A. Merkel,Paul R. Fortin,John A. Flynn,Geri A. Locker,Kirk A. Easley,Eric S. Schned,Gene G. Hunder,Michael C. Sneller,Carol Tuggle,Howard J. Swanson,J. Hernández-Rodríguez,Alfons López-Soto,Debora Bork,Diane B. Hoffman,Kenneth C. Kalunian,D. J. Klashman,William S. Wilke,Raymond J. Scheetz,Brian F. Mandell,Barri J. Fessler,Gregory S. Kosmorsky,Richard A. Prayson,Raashid Luqmani,George Nuki,Euan McRorie,Yvonne Sherrer,Shawn Baca,Bridgit Walsh,Diane Ferland,Martin Soubrier,Hyon K. Choi,Wolfgang L. Gross,Allen M. Segal,Charles Ludivico,Xavier Puéchal +43 more
TL;DR: The results of this randomized, multicenter trial do not support the adjunctive use of MTX to control disease activity or to decrease the cumulative dose and toxicity of CS in patients with GCA.
Journal ArticleDOI
Cyclophosphamide-Induced Cystitis and Bladder Cancer in Patients with Wegener Granulomatosis
Cheryl Talar-Williams,Y M Hijazi,M. M. Walther,W. M. Linehan,Claire W. Hallahan,Irina A. Lubensky,Gail S. Kerr,Gary S. Hoffman,Anthony S. Fauci,Michael C. Sneller +9 more
TL;DR: The incidence, clinical manifestations, and natural history of cyclophosphamide-mediated urotoxicity in a cohort of patients with Wegener granulomatosis are described and recommendations for surveillance are discussed.
Journal ArticleDOI
Infliximab for Maintenance of Glucocorticosteroid-Induced Remission of Giant Cell Arteritis: A Randomized Trial
Gary S. Hoffman,Maria C. Cid,Karen E. Rendt-Zagar,Peter A. Merkel,Cornelia M. Weyand,John H. Stone,Carlo Salvarani,W. Xu,Sudha Visvanathan,Mahboob Rahman +9 more
TL;DR: The first randomized, placebo-controlled, double-blind, multicenter trial of standardized treatment with glucocorticosteroids and adjunctive treatment with placebo or infliximab in patients with newly diagnosed giant cell arteritis found that inflIXimab did not reduce rates of relapse or any secondary end point.